Сиднокарба таблетки

Quick links

Choose a section

Quick links to important sections

Advertisements

Сиднокарба таблетки

Advertisements
Advertisements

Treatment option: Neurosis, Schizophrenia

Advertisements

Overview of Сиднокарба таблетки

Quick Facts

Property Description
Active ingredient Mesocarb (INN)
Form Tablet (Oral)
Pharmacological class Psychostimulant (CNS Stimulant)
General purpose Restores mental drive and physical tone
Origin Synthetic (Sydnonimine derivative)

What Type of Medicine Is Сиднокарба Таблетки?

Сиднокарба таблетки is a synthetic, single-component prescription medicine whose active ingredient is Mesocarb, designated by its International Nonproprietary Name (INN). It is classified pharmacologically as a psychostimulant and a psychotropic agent, specifically belonging to the chemical class of sydnonimine derivatives. The medicine is supplied as a tablet for oral administration.

The product's identity is defined by its core component, Mesocarb, utilized as the hydrochloride salt, alongside pharmaceutical excipients. This formulation is distinctive within its class and is characterized by its activity on dopamine reuptake.

The Pharmacological Nature and Origin of Mesocarb

Mesocarb is a non-amphetamine-type stimulant, a designation that provides a critical differentiation from traditional psychomotor stimulants. This synthetic compound is characterized by its unique chemical structure, which results in a distinct, prolonged duration of central nervous system stimulation. This characteristic is associated with promoting sustained wakefulness and mental clarity, unlike agents with shorter, more abrupt effects.

Historically, the formulation is unique to the pharmaceutical development of the former USSR and is today primarily utilized within successor states. Its specific mechanism of action provides a well-defined profile for targeting deficits in psychomotor activity.

What Is the General Purpose of Сиднокарба?

The fundamental purpose of this medication, derived from its classification, is to support individuals struggling with persistent states of diminished functional vitality, such as chronic apathy or significant fatigue. In a typical use scenario, the drug is intended to restore the capacity for effort and engagement when mental drive is compromised. The intended benefit is focused on improving the general ability to maintain concentration and physical tone.

Regulatory References

  1. Mesocarb (WHO ECDD Information)
Advertisements

What side effects are possible with Сиднокарба таблетки?

Possible Side Effects and Safety Information

The official safety profile for Сиднокарба (Mesocarb) is defined by its classification as a potent central nervous system (CNS) stimulant, leading to specific adverse reactions and usage constraints documented in regulatory sources.

Adverse Reaction Categories

Side effects documented in national regulatory labels are commonly grouped by the physiological system affected. The most frequently observed effects fall into the following classes:

  • Nervous System Disorders: Includes symptoms such as insomnia, excitability, anxiety, headache, and dizziness. These are consistent with the drug's stimulant effects on the CNS.
  • Cardiac Disorders: Involves effects on heart function, primarily tachycardia (increased heart rate) and, potentially, arrhythmia.
  • Gastrointestinal Disorders: May include symptoms like nausea, dry mouth, and loss of appetite (anorexia).

Safety Considerations and Regulatory Constraints

The medicine's regulatory safety documentation highlights specific constraints related to its stimulant activity. The potential for serious cardiovascular events, including pronounced hypertension and arrhythmia, is a significant safety consideration.

Due to this profile, the medicine is generally contraindicated in individuals with severe pre-existing conditions, such as severe cardiovascular disease, hypertension, or advanced atherosclerosis. Additionally, the substance has been documented to possess abuse liability and a potential for dependence associated with its long-term use, leading to its inclusion in international schedules for controlled substances. Time-related patterns indicate that effects such as insomnia and excitability may be more prominent at the start of treatment or following dose adjustments.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for overdose with Сиднокарба таблетки (Mesocarb) is characterized by the documented effects of excessive central nervous system stimulation.

Documented Clinical Manifestations

System Documented Signs
CNS Marked psychostimulant effect, increased mental and physical activity, excessive vitality or nervous energy.
Cardiovascular Tachycardia (elevated heart rate) and Hypertension (elevated blood pressure).

The presence of these documented signs—specifically the elevated heart rate and blood pressure—constitutes the official basis for regulatory findings on excessive exposure. These clinical findings are central to the regulatory understanding of Mesocarb overdose.

Emergency Action and Management

Official government regulatory information does not explicitly document specific instructions for immediate emergency action, such as detailed guidance on when to contact emergency services or specific clinical thresholds that trigger help-seeking.

Furthermore, specific procedural steps for supportive treatment (such as gastric lavage or the administration of activated charcoal) and information regarding the existence or absence of a specific antidote are not explicitly stated in the available regulatory documents. Any suspected ingestion above the prescribed level must be assessed considering the documented cardiovascular and CNS manifestations.

Advertisements

Therapeutic Uses of Сиднокарба таблетки

What Сиднокарба таблетки treats: main uses and benefits

The therapeutic application of Сиднокарба (Mesocarb) is commonly used to help manage symptoms related to persistent deficits in energy, motivation, and mental alertness, providing supportive relief in conditions marked by chronic functional decline. Its application is noted in clinical contexts involving various states of psychomotor reduction.

The medication is relevant for managing specific symptom clusters, including asthenia (pathological weakness), apathy, psychomotor slowness, and pathological hypersomnia. It is generally applied in clinical settings characterized by chronic fatigue states, severe attentional deficits, and adynamia. It helps manage symptoms associated with certain chronic conditions, providing support that may assist with initiating and maintaining activities and contributes to easing the symptom load related to functional stagnation.

Quick Fact: Relief for Functional Decline

Property Description
Target Symptoms Asthenia, Apathy, Attentional Deficits, Psychomotor Slowness
Primary Benefit Supports the management of symptoms that interfere with mental drive and physical capacity
Typical Context Chronic fatigue states and functional inertia
Symptom Type Persistent, pathological deficits in energy and motivation

Regulatory References

  1. WHO Expert Committee on Drug Dependence
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Сиднокарба Таблетки (Mesocarb)

Official regulatory documents define strict population eligibility for Mesocarb, with prohibitions that vary by jurisdiction. The drug is prohibited for all medical use in the United States, as it is classified as a Schedule I controlled substance lacking accepted medical safety.

In regions where the medicine is approved, eligibility is highly restricted. Absolute contraindications include pregnancy, lactation, and use in children.

Contraindicated Conditions

Regulatory labeling specifies that Mesocarb must not be used by patients with:

  • Acute Circulatory Insufficiency, including cardiogenic shock or marked arterial hypotension.
  • Acute Myocardial Infarction or acute angina.
  • Chronic cardiovascular diseases such as arterial hypertension and atherosclerosis.
  • CNS conditions including psychomotor agitation and glaucoma (especially closed-angle).

Restricted and Conditional Use

Use is only permitted with caution in certain populations. This includes older adults (geriatric patients) and individuals with documented impaired hepatic (liver) or renal (kidney) function. Caution is also specified for patients with a history of hemorrhagic stroke or increased intracranial pressure.

Advertisements

What should I know about interactions with other medicines?

Drug Interactions with Sydnocarb

Sydnocarb (Mesocarb), a psychostimulant, can interact with various medications, primarily due to its effects on the central nervous system (CNS) and neurotransmitter systems, specifically dopamine and norepinephrine reuptake.

Serious and Contraindicated Interactions

The most significant and potentially dangerous interaction is with Monoamine Oxidase Inhibitors (MAOIs), including certain antidepressants, Parkinson's medications, and antibiotics (e.g., linezolid). Concurrent use or use within a two-week washout period can lead to an excessive accumulation of neurotransmitters, significantly increasing the risk of severe side effects such as a hypertensive crisis (dangerously high blood pressure) or Serotonin Syndrome (a life-threatening condition involving changes in mental status, autonomic instability, and neuromuscular abnormalities).

Drug Class Potential Effect Recommendation
MAO Inhibitors Hypertensive Crisis, Serotonin Syndrome Contraindicated. Avoid within 14 days of each other.
Other CNS Stimulants Amplified stimulant effects (e.g., increased heart rate, elevated blood pressure) Use with extreme caution; may require dose adjustment.

Interactions Affecting Efficacy and Side Effects

  • Antihypertensive Medications: Sydnocarb's stimulant properties, which can increase heart rate and blood pressure, may counteract the effects of drugs used to lower blood pressure.
  • CNS Depressants: Sydnocarb may diminish or shorten the duration of action of sedative or hypnotic agents.
  • Antipsychotics/Dopamine Antagonists (e.g., Haloperidol): These agents can potentially block the central stimulating effects of Sydnocarb, reducing its therapeutic efficacy.

It is essential to inform your healthcare provider about all prescription and over-the-counter medicines, vitamins, and supplements to effectively manage potential interactions.

Advertisements

Mechanism of Action

How Сиднокарба таблетки works: Mechanism of Action

The medication acts primarily as a reuptake inhibitor within the central nervous system. Its main molecular targets are the Dopamine Transporter (DAT) and, to a lesser degree, the Norepinephrine Transporter (NET), both of which are located on the presynaptic terminal membrane. By binding to these transporters, the drug blocks the natural reuptake mechanism responsible for clearing the neurotransmitters dopamine and norepinephrine from the synaptic cleft.

This action results in a sustained elevation of active monoamines within the brain’s communication spaces. The increased availability of these neurotransmitters enhances signaling in specific central pathways, including those that govern wakefulness, vigilance, and motor control. This targeted potentiation contributes to a generalized state of heightened neuronal excitability, leading to a physiological adjustment that involves increased neuronal activity in systems related to alertness and sustained psychomotor activity.

Advertisements

Dosage and Administration Information

The established usage patterns for Сиднокарба tablets (Mesocarb) follow prescribing information developed for its medical application. These guidelines focus on clinical administration protocols for psychotropic substances.

Administration Overview

The medication is prescribed for oral administration in its tablet form. The drug’s inherent pharmacological properties provide a prolonged duration of action, which affects the dosing schedule and allows for less frequent daily administration compared to agents with rapid clearance.

Usage Parameter Standard Protocol
Route of Administration Oral (Tablet form)
Dosing Frequency Less frequent due to prolonged action time
Dose Initiation Must begin with low dose titration

Dosing and Procedural Regimens

The dosing regimen requires the initiation of the medicine at a minimal effective level. The initial quantity typically ranges from 5 to 15 milligrams per day. The dosing schedule is defined by a principle of gradual titration, where adjustments are made slowly to establish a therapeutic maintenance level. The prescribing information defines the upper limit for administration; the total dose per 24-hour period is generally required not to exceed 50 milligrams. Throughout the course of use, proper administration requires that the patient avoid abrupt changes in the dosage or immediate cessation of the schedule. This procedural restraint is a core component of the administration protocol.

Advertisements

Recent Clinical Evidence

Сиднокарба таблетки: Recent Clinical Evidence (Mesocarb)

This section provides an objective summary of the available research and clinical studies for Mesocarb. The purpose is to describe what has been studied and what remains uncertain, without offering medical advice or making claims about the drug's effectiveness. Research findings describe group patterns, not personal outcomes.


Research Evidence Overview

The evidence base is divided into two distinct areas: historical studies derived from decades of clinical use, focusing on deficits in mental drive and energy, and modern, exploratory research in specialized neurological conditions. It is important to note that foundational evidence comes from studies whose methods differ from current international Randomized Controlled Trial (RCT) standards.


Evidence for Use in Chronic Fatigue, Apathy, and Asthenia

This historical research examined its application in individuals presenting with persistent reductions in energy and physical tone, such as asthenia and apathy. Studies monitored outcomes reflecting daily functioning, including measurements of physical work capacity and psychomotor activity. Regulatory bodies reviewing this data indicated that the findings indicated that the evidence level was estimated to be between little and moderate based on the data available at the time. A research limitation is that the original trials' methodologies do not align with modern RCT protocols.


Evidence for Use in Specialized Neurological Conditions

This area of research represents exploratory development for a specific application in a sub-population of patients with Parkinson’s disease (PD), particularly Levodopa-Induced Dyskinesia (LID). Studies are primarily early-phase (Phase 1/2) clinical trials and pre-clinical models. The outcomes monitored include changes in scores that measure dyskinesia severity and patterns related to sleep-wake cycle stabilization. Data are still emerging, and certainty remains low regarding definitive clinical effects.


Summary of Key Evidence Gaps and Limitations

A significant record of use exists from decades of cumulative post-marketing exposure, but long-term effects are not fully established based on modern epidemiological standards. Comparative evidence is lacking; research examining the medicine against other treatments is scarce. Subgroup findings are uncertain, as data for certain groups remain insufficient.

Key Studies & References

  1. WHO Expert Committee on Drug Dependence (Mesocarb) review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Сиднокарба таблетки (FAQ)


Q: How long does it take for Sydnocarb to start working?

Official information highlights that Sydnocarb (Mesocarb) is characterized by a prolonged duration of action. This characteristic provides for a prolonged effect, which is why official administration protocols typically require less frequent dosing compared to agents with rapid clearance. The specific timeframe for the onset of effects is not generally detailed in patient documentation.


Q: Does Sydnocarb affect blood pressure?

Yes, regulatory information states that the medicine can affect the cardiovascular system, potentially leading to increased blood pressure and a faster heart rate (tachycardia). Official guidance indicates that Sydnocarb is generally contraindicated in individuals with severe pre-existing hypertension or advanced cardiovascular conditions.


Q: Can Sydnocarb affect appetite or weight?

Official safety documents list changes to the gastrointestinal system, including loss of appetite (anorexia), as a possible side effect. While the regulatory information does not directly describe effects on body weight, changes in appetite are a documented possibility.


Q: Are there driving restrictions when taking Sydnocarb?

Because the drug's possible side effects include nervous system issues such as dizziness, excitability, and insomnia, caution is required. Regulatory labeling highlights the need for caution regarding activities that demand high focus, such as driving or operating machinery.


Q: Is it true that Sydnocarb is used to treat asthenia?

Studies and clinical data reviews describe the drug's historical use and examination in individuals experiencing asthenia, which is a persistent reduction in physical and mental energy. This application aligns with its general purpose, which official documentation describes as restoring diminished mental drive and psychomotor activity.


Q: Is Sydnocarb classified as a narcotic substance?

The active substance is included in international schedules for controlled psychotropic substances. For example, it is included in Schedule IV of the United Nations 1971 Convention. For instance, in the United States, it is designated as a Schedule I controlled substance.


Q: Is Sydnocarb an antibiotic or another type of medicine?

No, Sydnocarb is not an antibiotic. According to official pharmacological classifications, it belongs to the class of psychostimulants. It is a synthetic compound that acts on the central nervous system to enhance alertness and psychomotor activity.


Q: Does Sydnocarb have any relation to the antidepressant group?

The official pharmacological classification designates this medicine as a psychostimulant. While its mechanism involves inhibiting the reuptake of neurotransmitters like dopamine and norepinephrine—a process seen in some other drug classes—regulatory documents do not classify it directly as an antidepressant.


Q: Can Sydnocarb be used to lift one's mood?

The officially described general purpose of the medicine focuses on restoring mental drive, energy, and the capacity for sustained concentration. According to official documentation, the drug's intended benefit is focused on concentration, rather than functioning as a primary mood enhancer.


Q: How does Sydnocarb differ from other medicines with similar names?

Official documentation emphasizes that Sydnocarb is a synthetic psychostimulant and is chemically distinct from amphetamine-type stimulants. Its unique chemical structure, a sydnonimine derivative, is cited as providing its defined pharmacological profile and prolonged effects.


Q: Are there analogs of Sydnocarb with the same active substance?

The active substance, Mesocarb, may be found under various other commercial names across different jurisdictions. These can include brand names such as Sydnokarb, Sydnocarbum, and Pharmaneocarb, depending on the region and manufacturer.


Q: Does Sydnocarb really belong to the 'nootropic' class?

The primary regulatory classification of Sydnocarb is as a central nervous system (CNS) psychostimulant. While the drug was historically used or explored in contexts related to improving cognitive functions, its official designation remains within the stimulant class.


Q: Why is Sydnocarb banned in some countries?

Official bodies, such as in the United States, have classified the drug as a Schedule I controlled substance. This designation is given to substances determined to lack an accepted medical use, possess a high potential for abuse, and lack accepted safety for medical use under supervision.


Q: Does Sydnocarb affect concentration?

Yes, the described purpose of the medicine is to support individuals with diminished functional vitality, focusing on improving the general ability to maintain concentration. The mechanism of action is linked to enhancing signaling in pathways that govern vigilance and alertness.


Q: What is 'withdrawal syndrome' when stopping Sydnocarb?

Due to the drug’s potential for dependence, regulatory documents specify that abrupt discontinuation or sudden changes in dosage must be avoided. This procedural restraint is implemented because the drug's classification implies a potential for dependence, which may result in physical or psychological reactions if stopped abruptly.


Q: Can Sydnocarb be taken with coffee?

Official product information does not specify guidance regarding consumption of coffee or caffeine. However, regulatory instructions caution against the concurrent use of Sydnocarb with other central nervous system stimulants due to the risk of amplified side effects, such as increased heart rate and nervousness.


Q: Sydnocarb and sports — are there special administration features?

Yes, the active substance, Mesocarb, is included on the World Anti-Doping Agency (WADA) Prohibited List. This authoritative designation indicates that the use of this medicine is forbidden for athletes and individuals engaged in competitive sports, according to WADA regulations.


Q: Why is a doctor's consultation needed before starting Sydnocarb?

A consultation is required before starting this medicine because it is a prescription drug with a specific risk profile. A consultation is required so the provider can assess for absolute contraindications, such as severe cardiovascular disease or pregnancy, and check for potential drug interactions as required by official guidelines.


Q: Are there studies of Sydnocarb on children?

While there is historical documentation of the drug being studied or used in specific contexts related to children, current official instructions state that use in children is an absolute contraindication for the medicine.


Q: Why are the official instructions for Sydnocarb so long?

Regulatory bodies mandate that drug manufacturers provide comprehensive documentation detailing all established scientific and safety information. This includes a full description of indications, contraindications, every known side effect, and all potential drug interactions, which results in lengthy official instructions.


Q: Can I take Sydnocarb if I am already taking other nervous system medications?

Official product information describes serious interactions with several classes of drugs that affect the nervous system. These include MAO Inhibitors, other CNS stimulants, and CNS depressants. Any co-administration with these types of medicines requires mandatory management and control by a healthcare provider.


Q: What does 'prolonged action' mean in the context of Sydnocarb?

Prolonged action refers to the extended length of time the pharmacological effects of the medicine remain active in the body. This characteristic allows for less frequent administration compared to medicines with a rapid clearance rate, as specified in the administration principles.


Q: Is a prescription needed to buy Sydnocarb tablets?

Yes, Sydnocarb is classified as a prescription medicine and a controlled substance. As a result, the medicine can only be obtained through a valid prescription issued by an authorized healthcare provider.


Q: Sydnocarb and other CNS stimulants?

Official safety information highlights the risk of combining Sydnocarb with other central nervous system (CNS) stimulants, as this may lead to amplified stimulant effects. This potential interaction requires extreme caution.

Advertisements

How should Сиднокарба таблетки be stored and disposed of?

The storage and disposal requirements for Сиднокарба таблетки (Mesocarb) are defined by the official regulatory labeling to ensure product quality and safety.

Official Storage and Stability

The product does not require any special storage conditions in terms of temperature, light, or humidity. This lack of restriction allows for the maintenance of the full labeled shelf-life of 2 years under normal conditions.

Storage Requirement Official Regulatory Statement
Temperature / Environment Does not require any special storage conditions.
Shelf-Life 2 years.

Child-Safety and Disposal

For safety, the medicine must be kept out of the sight and reach of children to prevent accidental ingestion. When the product is expired or unused, there are no special requirements for its disposal, which means it should be discarded in accordance with local general pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Сиднокарба таблетки found in:

A-Z Index: